[1] |
HELLSTRÖM-LINDBERG E, TOBIASSON M, GREENBERG P. Myelodysplastic syndromes:moving towards personalized management[J]. Haematologica, 2020, 105(7):1765-1779. DOI: 10.3324/haematol.2020.248955.
|
[2] |
ARBER D A, ORAZI A, HASSERJIAN R,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405. DOI: 10.1182/blood-2016-03-643544.
|
[3] |
GARCIA-MANERO G, CHIEN K S, MONTALBAN-BRAVO G. Myelodysplastic syndromes:2021 update on diagnosis,risk stratification and management[J]. Am J Hematol, 2020, 95(11):1399-1420. DOI: 10.1002/ajh.25950.
|
[4] |
DELLA PORTA M G, PICONE C, PASCUTTO C,et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes:results of a European LeukemiaNET study[J]. Haematologica, 2012, 97(8):1209-1217. DOI: 10.3324/haematol.2011.048421.
|
[5] |
DELLA PORTA M G, PICONE C. Diagnostic utility of flow cytometry in myelodysplastic syndromes[J]. Mediterr J Hematol Infect Dis, 2017, 9(1):e2017017. DOI: 10.4084/MJHID.2017.017.
|
[6] |
CREMERS E M, WESTERS T M, ALHAN C,et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes[J]. Haematologica, 2017, 102(2):320-326. DOI: 10.3324/haematol.2016.147843.
|
[7] |
OELSCHLAEGEL U, OELSCHLAEGER L, VON BONIN M,et al. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes:diagnostic power and prognostic impact[J]. Cytometry B Clin Cytom, 2021. DOI: 10.1002/cyto.b.22030.
|
[8] |
WESTERS T M, IRELAND R, KERN W,et al. Standardization of flow cytometry in myelodysplastic syndromes:a report from an international consortium and the European LeukemiaNet Working Group[J]. Leukemia, 2012, 26(7):1730-1741. DOI: 10.1038/leu.2012.30.
|
[9] |
PORWIT A, VAN DE LOOSDRECHT A A, BETTELHEIM P,et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS[J]. Leukemia, 2014, 28(9):1793-1798. DOI: 10.1038/leu.2014.191.
|
[10] |
MCGOWAN-JORDAN J, SIMONS A, SCHMID M,et al. ISCN 2016:An International System for Human Cytogenomic Nomenelature(2016)[S]. Basel:Karger, 2016. alsoin Cytogenet Genome Res, 2016, 149:1-140. DOI: 10.1159/isbn.978-3-318-06861-0.
|
[11] |
GREENBERG P L, TUECHLER H, SCHANZ J,et al. Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465. DOI: 10.1182/blood-2012-03-420489.
|
[12] |
|
[13] |
SWERDLOW S H, CAMPO E, HARRIS N L,et al. WHO Classification of Tumours of Haematopoietic and Lymphoid tissues (Revised 4th edition)[M]. IARC:Lyon,2017:103.
|
[14] |
MATHIS S, CHAPUIS N, DEBORD C,et al. Flow cytometric detection of dyserythropoiesis:a sensitive and powerful diagnostic tool for myelodysplastic syndromes[J]. Leukemia, 2013, 27(10):1981-1987. DOI: 10.1038/leu.2013.178.
|
[15] |
VAN DE LOOSDRECHT A A, WESTERS T M. Cutting edge:flow cytometry in myelodysplastic syndromes[J]. J Natl Compr Canc Netw, 2013, 11(7):892-902. DOI: 10.6004/jnccn.2013.0106.
|
[16] |
WESTERS T M, CREMERS E M P, OELSCHLAEGEL U,et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group[J]. Haematologica, 2017, 102(2):308-319. DOI: 10.3324/haematol.2016.147835.
|
[17] |
VAN DE LOOSDRECHT A A, KERN W, PORWIT A,et al. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome:a report of the European LeukemiaNet International MDS-Flow Cytometry Working Group[J]. Cytometry B Clin Cytom, 2021. DOI: 10.1002/cyto.b.22044.
|
[18] |
JOHANSSON U, MCIVER-BROWN N, CULLEN M,et al. The flow cytometry myeloid progenitor count:a reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes[J]. Cytometry B Clin Cytom, 2021. DOI: 10.1002/cyto.b.22048.
|
[19] |
BEHBEHANI G K, FINCK R, SAMUSIK N,et al. Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation[J]. Cytometry B Clin Cytom, 2020, 98(2):131-145. DOI: 10.1002/cyto.b.21860.
|
[20] |
BACHAS C, DUETZ C, VAN SPRONSEN M F,et al. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry[J]. Cytometry B Clin Cytom, 2022. DOI: 10.1002/cyto.b.22066.
|
[21] |
CHAUHAN R, SINGH J, SHARMA C,et al. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study[J]. Leuk Res, 2021, 107:106651. DOI: 10.1016/j.leukres.2021.106651.
|
[22] |
MAJCHEREK M, KIERNICKA-PARULSKA J, MIERZWA A,et al. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience[J]. Scand J Immunol, 2021, 94(2):e13028. DOI: 10.1111/sji.13028.
|
[23] |
JOHANSSON U, ROLF N, FUTHEE N,et al. Erythroid side scatter:a parameter that improves diagnostic accuracy of flow cytometry myelodysplastic syndrome scoring[J]. Cytometry B Clin Cytom, 2022. DOI: 10.1002/cyto.b.22067.
|
[24] |
DELLA PORTA M G, PICONE C, TENORE A,et al. Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia[J]. Haematologica, 2014, 99(1):e8-10. DOI: 10.3324/haematol.2013.097188.
|
[25] |
CORRAO K, REZWAN S, ATALLAH E,et al. Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome[J]. Leuk Res Rep, 2022, 17:100329. DOI: 10.1016/j.lrr.2022.100329.
|